Two-Drug combo tested as new hope for Tough-to-Treat cancers
Disease control
Terminated
This study tested whether adding an experimental drug called SOT101 to an existing immunotherapy (pembrolizumab) could help control advanced cancers that had stopped responding to other treatments. It involved 166 adults with specific advanced solid tumors, including lung, colore…
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC